Find us on Social Media:

Branched Chain Amino Acids (BCAAs)
What is it? Overview Usage Side Effects and Warnings

Branched Chain Amino Acids (BCAAs) Overview

Written by FoundHealth.

Branched-chain amino acids (BCAAs) are naturally occurring molecules (leucine, isoleucine, and valine) that the body uses to build proteins. The term "branched chain" refers to the molecular structure of these particular amino acids. Muscles have a particularly high content of BCAAs.

For reasons that are not entirely clear, BCAA supplements may improve appetite in cancer patients and slow the progression of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease, a terrible condition that leads to degeneration of nerves, atrophy of the muscles, and eventual death).

BCAAs have also been proposed as a supplement to boost athletic performance.


Dietary protein usually provides all the BCAAs you need. However, physical stress and injury can increase your need for BCAAs to repair damage, so supplementation may be helpful.

BCAAs are present in all protein-containing foods, but the best sources are red meat and dairy products. Chicken, fish, and eggs are excellent sources as well. Whey protein and egg protein supplements are another way to ensure you're getting enough BCAAs. Supplements may contain all three BCAAs together or simply individual BCAAs.

Therapeutic Dosages

The typical dosage of BCAAs is 1 g to 5 g daily.

What Is the Scientific Evidence for Branched Chain Amino Acids?

Appetite in Cancer Patients

A double-blind study tested BCAAs on 28 people with cancer who had lost their appetites due to either the disease itself or its treatment. 1 Appetite improved in 55% of those taking BCAAs (4.8 g daily) compared to only 16% of those who took placebo.

Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)

A small double-blind study found evidence that BCAAs might help protect muscle strength in people with Lou Gehrig's disease . 2 Eighteen individuals were given either BCAAs (taken 4 times daily between meals) or placebo and followed for 1 year. The results showed that people taking BCAAs declined much more slowly than those receiving placebo. In the placebo group, 5 of 9 participants lost their ability to walk, 2 died, and another required a respirator. Only 1 of the 9 participants receiving BCAAs became unable to walk during the study period. This study is too small to give conclusive evidence, but it does suggest that BCAAs might be helpful for this disease.

However, other studies found no effect, 3 and one actually found a slight increase in deaths during the study period among those treated with BCAAs compared to placebo. 4

Muscular Dystrophy

One double-blind, placebo-controlled study found leucine (one of the amino acids in BCAAs) ineffective at the dose of 0.2 g per kilogram body weight (for example, 15 g daily for a 75-kilogram woman) in 96 individuals with muscular dystrophy. 5 Over the course of 1 year, no differences were seen between the effects of leucine and placebo.


  1. Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Natl Cancer Inst. 88(8):550-2.
  2. Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet. 1(8593):1015-8.
  3. Testa D, Caraceni T, Fetoni V. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol. 236(8):445-7.
  4. [No authors listed]. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Italian ALS Study Group. Neurology. 1993;43:2466-2470.
  5. Mendell JR, Griggs RC, Moxley RT III, et al. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine. Muscle Nerve. 1984;7:535-541.


No one has made any comments yet. Be the first!

Your Comment